Copy

WHO recommends dolutegravir as preferred HIV treatment

Share Share
Tweet Tweet
Forward Forward
Share Share
Based on new evidence assessing benefits and risks, WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.

DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance.
Read the press release
More about HIV
In case you missed it ....

WHO/EURO studies find baby foods are high in sugar 

Two new studies from WHO/Europe show that a high proportion of baby foods are incorrectly marketed as suitable for infants under the age of 6 months, and that many of those foods contain inappropriately high levels of sugar.

WHO’s long-standing recommendation states that children should be breastfed, exclusively, for the first 6 months.

Read the press release
Share Share
Tweet Tweet
Forward Forward
Share Share
Subscribe to our weekly updates here
 
Copyright © 2019 World Health Organization, All rights reserved. 
You are receiving this email because you signed up for updates at the WHO website (www.who.int). Thanks for helping to make the world a little healthier. 

Our mailing address is: 
World Health Organization
Avenue Appia 20
Geneva 27 1211
Switzerland
Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
World Health Organization · Avenue Appia 20 · Geneva 27 1211 · Switzerland